Press release as PDF

Medivir presents at the Jefferies Global Healthcare Conference

Medivir will participate in, and present at, the Jefferies 2013 Global Healthcare Conference in New York.

Slides from the presentation will be available on Medivir's website under the Financial Reports/Latest events tab, as of Tuesday 4 June.


For more information please contact:

Rein Piir, EVP Corporate Affairs & IR
Mobile: +46 708 537 292

About Medivir
Medivir is an emerging research-based pharmaceutical company focused on infectious diseases.
Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir, a novel protease inhibitor in late phase III clinical development for hepatitis C that is being developed in collaboration with Janssen R&D Ireland. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.

For more information about Medivir AB, please visit the Company’s website: www.medivir.com


Medivir is a collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C. We are passionate and uncompromising in our mission to develop and commercialize innovative pharmaceuticals that improve people’s lives.


Page updated 15 maj 2017